Další formáty:
BibTeX
LaTeX
RIS
@article{1612496,
author = {Poprach, Alexandr and Rumanová, Kristína and Lakomý, Radek and Chloupková, Renata and Staník, Michal and Pokrivčák, Tomáš and Kiss, Igor and Slabý, Ondřej and Studentova, Hana and Melichar, Bohuslav and Juráček, Jaroslav and Fiala, Ondrej and Kopecky, Jindrich and Kopeckova, Katerina and Zemanova, Milada and Büchler, Tomáš},
article_location = {New York},
article_number = {4},
doi = {http://dx.doi.org/10.1016/j.urolonc.2018.12.017},
keywords = {Nonclear cell renal carcinoma; Targeted therapy; Sunitinib; Pazopanib},
language = {eng},
issn = {1078-1439},
journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
title = {Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database},
url = {http://dx.doi.org/10.1016/j.urolonc.2018.12.017},
volume = {37},
year = {2019}
}
TY - JOUR
ID - 1612496
AU - Poprach, Alexandr - Rumanová, Kristína - Lakomý, Radek - Chloupková, Renata - Staník, Michal - Pokrivčák, Tomáš - Kiss, Igor - Slabý, Ondřej - Studentova, Hana - Melichar, Bohuslav - Juráček, Jaroslav - Fiala, Ondrej - Kopecky, Jindrich - Kopeckova, Katerina - Zemanova, Milada - Büchler, Tomáš
PY - 2019
TI - Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database
JF - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL - 37
IS - 4
SP - „294e1“-„294e8“
EP - „294e1“-„294e8“
PB - ELSEVIER SCIENCE INC.
SN - 10781439
KW - Nonclear cell renal carcinoma
KW - Targeted therapy
KW - Sunitinib
KW - Pazopanib
UR - http://dx.doi.org/10.1016/j.urolonc.2018.12.017
L2 - http://dx.doi.org/10.1016/j.urolonc.2018.12.017
N2 - Background: Nonclear cell renal cell carcinoma (nccRCC) is a heterogeneous group of primary kidney tumors. The aim of the present retrospective study was to analyze outcomes of patients with nccRCC treated with tyrosine-kinase inhibitors (TKIs) based on a national registry. Methods: The registry contained evaluable data of 93 nccRCC patients treated with first-line TKIs, including 87 patients with papillary renal cell carcinoma (RCC) and 6 patients with chromophobe RCC. The control cohort consisted of 1,788 patients with clear-cell RCC treated with firstline TKIs. Multivariable Cox proportional hazard model was used to evaluate the effect of potential prognostic factors on the survival measures. Results: Median progression-free survival was 11.8 and 6.5 months in the clear cell renal cell carcinoma and nccRCC patients, respectively (P = 0.018), and median overall survival was 33.2 and 22.0 months, respectively (P = 0.007). In the multivariate analysis, independent factors associated with inferior progression-free survival included high tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, and sunitinib (as opposed to pazopanib) as first-line targeted therapy. Independent predictors of inferior overall survival included nonclear cell histology, tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, older age, and sunitinib as first-line targeted therapy. Conclusions: The present retrospective, registry-based study confirms that patients with nccRCC treated with TKIs have worse clinical outcomes compared to clear cell renal cell carcinoma patients with similar baseline characteristics. (C) 2018 Elsevier Inc. All rights reserved.
ER -
POPRACH, Alexandr, Kristína RUMANOVÁ, Radek LAKOMÝ, Renata CHLOUPKOVÁ, Michal STANÍK, Tomáš POKRIVČÁK, Igor KISS, Ondřej SLABÝ, Hana STUDENTOVA, Bohuslav MELICHAR, Jaroslav JURÁČEK, Ondrej FIALA, Jindrich KOPECKY, Katerina KOPECKOVA, Milada ZEMANOVA a Tomáš BÜCHLER. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., roč.~37, č.~4, s.~„294e1“-„294e8“, 8 s. ISSN~1078-1439. doi:10.1016/j.urolonc.2018.12.017. 2019.
|
